Drug Profile
Lyophilised Oxalobacter formigenes - OxThera AB
Alternative Names: IxOC 3; Lyophylised Oxalobacter formigenes; OC 3; OC5; Oxabact; Oxabact OC5 - Oxalobacter formigenes HC-1; OxalobacterLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Ixion Biotechnology
- Developer OxThera
- Class Bacteria; Probiotics
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Primary hyperoxaluria
- No development reported Short bowel syndrome
Most Recent Events
- 22 Feb 2023 Phase III clinical development is still ongoing in Primary hyperoxaluria (In children, In adolescents, In adults, In the elderly) in United Kingdom, USA, Belgium, Tunisia and France (PO) (OxThera AB pipeline, February 2023)
- 03 Sep 2021 OxThera terminates a phase III ePHex-OLE extension study in Primary hyperoxaluria (In adolescents, In children, In the elderly, In adults) in Belgium, Germany, Spain and United Kingdom as the parent trial OC5-DB-02 did not achieve primary endpoint (PO) (NCT03938272)
- 11 Jun 2021 Efficacy and adverse events data from a phase III OC5-DB-02 trial in Primary hyperoxaluria released by OxThera